Peters says that 90 percent of those who responded to the treatment “continued to have marked clinical improvement in both pain and frequency symptoms. ”
Peters ütleb, et 90 protsendil patsientidest, kes allusid ravile, „püsisid kliinilised näidud alanenud valu ja urineerimissageduse näol märkimisväärselt head ”.